Anti-glycoprotein-210 antibodies

AutoAbBox
Autoantigen = glycoprotein-210
OneIsoform = Yes
OneIsoformSpecialName = Nucleoporin 210kDa
OneGene = NUP210
OneOrgan = Bile Duct
OneTissue =
OneCell =
OneAlso =
OneDisease = Primary biliary cirrhosis
OneIgClass =
OneIgGSubclass =
OneHLA1 = DR2 (weak)
OneHLA2 =
OneHLA3 =
OneAssociatedGene =
OneTCellRestr =
OneTrigger =

Anti-glycoprotein-210 antibodies (AGPA, anti-gp210, anti-nup210, anti-np210) are directed at gp210cite journal | author = Courvalin JC, Lassoued K, Worman HJ, Blobel G | title = Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis | journal = J. Exp. Med. | volume = 172 | issue = 3 | pages = 961–7 | year = 1990 | pmid = 2167346 | doi = ] and are found within primary biliary cirrhosis (PBC) patients in high frequency. AGPA recognize the cytoplasmic oriented carboxyl terminus (tail) of the protein.cite journal | author = Nickowitz RE, Worman HJ | title = Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210 | journal = J. Exp. Med. | volume = 178 | issue = 6 | pages = 2237–42 | year = 1993 | pmid = 7504063 | doi = ] While AGPA is found as a prognostic marker in only a minority of PBC patients those that did had higher mortality and predicts a poor outcome.cite journal | author = Itoh S, Ichida T, Yoshida T, "et al" | title = Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis | journal = J. Gastroenterol. Hepatol. | volume = 13 | issue = 3 | pages = 257–65 | year = 1998 | pmid = 9570238 | doi = ] In addition patients that responded to ursodeoxycholic acid (UDCA) therapy and, therefore, had AGPA reductions failed to develop end-stage liver disease relative to untreated cohort with anti-gp210 Ab.cite journal | author = Nakamura M, Shimizu-Yoshida Y, Takii Y, "et al" | title = Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis | journal = J. Hepatol. | volume = 42 | issue = 3 | pages = 386–92 | year = 2005 | pmid = 15710222 | doi = 10.1016/j.jhep.2004.11.016] PBC patients with potentially destructive AGPA have increased expression of Nup210 in the bile duct, a potential immune tolerance-escaping factor.cite journal | author = Nakamura M, Takii Y, Ito M, "et al" | title = Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis | journal = J. Autoimmun. | volume = 26 | issue = 2 | pages = 138–45 | year = 2006 | pmid = 16337775 | doi = 10.1016/j.jaut.2005.10.007]

Anti-mitochondrial, anti-centromerecite journal | author = Nakamura M, Kondo H, Mori T, "et al" | title = Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | journal = Hepatology | volume = 45 | issue = 1 | pages = 118–27 | year = 2007 | pmid = 17187436 | doi = 10.1002/hep.21472] and anti-p62 antibodies are also found in (PBC). While patients with AGPA progress toward end-stage liver failure, patients with anti-centromere antibodies often progress toward portal hypertension, further indicating a specific role of the AGPA in PBC.

Notes

gp210 is commonly used in the literature. The gene, NUP210, encodes the Nuclear pore (Nuclear porin) glycoprotein-210 that is a major component of the human nuclear pore complex.

References